公开(公告)号：US20240252499A1

公开(公告)日：2024-08-01

申请号：US18423217

申请日：2024-01-25

Applicant: CymaBay Therapeutics, Inc.

Inventor： Yun-Jung Choi ,  Charles A. McWherter

IPC: A61K31/5375 ,  A61K9/00 ,  A61K31/192 ,  A61P13/12 ,  A61P17/04

CPC classification number: A61K31/5375 ,  A61K9/0014 ,  A61K9/0053 ,  A61K31/192 ,  A61P13/12 ,  A61P17/04

Abstract: Treatment of uremic pruritus by administration of seladelpar or a salt thereof, or by administration of mavodelpar or a salt thereof.

公开(公告)号：US11596614B2

公开(公告)日：2023-03-07

申请号：US17221784

申请日：2021-04-03

Applicant: CymaBay Therapeutics, Inc.

Inventor： Pol Boudes ,  Charles A. McWherter

IPC: A61K31/192 ,  A61K9/00

Abstract: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.

公开(公告)号：US20210283078A1

公开(公告)日：2021-09-16

申请号：US17128195

申请日：2020-12-21

Applicant: CymaBay Therapeutics, Inc.

Inventor： Pol Boudes ,  Charles A. McWherter ,  Alexandra S. Steinberg

IPC: A61K31/192 ,  A61P1/16 ,  A61K9/00

Abstract: Treatment of cholestatic pruritus by therapy with seladelpar or a salt thereof.

公开(公告)号：US20210023031A1

公开(公告)日：2021-01-28

申请号：US17062545

申请日：2020-10-03

Applicant: CymaBay Therapeutics, Inc.

Inventor： Pol Boudes ,  Charles A. McWherter

IPC: A61K31/192 ,  A61K31/09

Abstract: Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.

公开(公告)号：US20210000774A1

公开(公告)日：2021-01-07

申请号：US17024971

申请日：2020-09-18

Applicant: CymaBay Therapeutics, Inc.

Inventor： Pol Boudes ,  Charles A. McWherter

IPC: A61K31/192 ,  A61K9/00

Abstract: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.

公开(公告)号：US20200061006A1

公开(公告)日：2020-02-27

申请号：US16597313

申请日：2019-10-09

Applicant: CymaBay Therapeutics, Inc.

Inventor： Pol Boudes ,  Charles A. McWherter

IPC: A61K31/192 ,  A61K9/00

Abstract: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.

公开(公告)号：US10342770B2

公开(公告)日：2019-07-09

申请号：US16222379

申请日：2018-12-17

Applicant: CymaBay Therapeutics, Inc.

Inventor： Brian Roberts ,  Xueyan Wang ,  Yun-Jung Choi ,  David Karpf ,  Robert Martin ,  Charles McWherter

IPC: A61K31/192 ,  A61K31/33 ,  A61K9/00

Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.

公开(公告)号：US20190192459A1

公开(公告)日：2019-06-27

申请号：US16222325

申请日：2018-12-17

Applicant: CymaBay Therapeutics, Inc.

Inventor： Pol Boudes ,  Charles A. McWherter

IPC: A61K31/192 ,  A61K31/09

Abstract: Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.

公开(公告)号：US20150290154A1

公开(公告)日：2015-10-15

申请号：US14684100

申请日：2015-04-10

Applicant: CymaBay Therapeutics, Inc.

Inventor： Brian Roberts ,  Xueyan Wang ,  Yun-Jung Choi ,  David Karpf ,  Robert Martin ,  Charles McWherter

IPC: A61K31/192

CPC classification number: A61K31/192 ,  A61K9/0053 ,  A61K31/33

Abstract: Treatment of NAFLD and NASH by therapy with MBX-8025 or an MBX-8025 salt.

Abstract translation: 用MBX-8025或MBX-8025盐治疗NAFLD和NASH。

公开(公告)号：US20150258053A1

公开(公告)日：2015-09-17

申请号：US14667145

申请日：2015-03-24

Applicant: CymaBay Therapeutics, Inc.

Inventor： Brian K. Roberts ,  Gopal Chandra Saha ,  Brian Edward Lavan ,  Charles A. McWherter

IPC: A61K31/216 ,  A61K31/426

CPC classification number: A61K31/426 ,  A61K9/0095 ,  A61K9/10 ,  A61K9/20 ,  A61K9/48 ,  A61K31/192 ,  A61K31/216 ,  A61K31/222 ,  A61K31/519 ,  A61K45/06 ,  A61K2300/00

Abstract: Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.

Abstract translation: 本文公开了用于降低受试者的血清尿酸水平和用于治疗与升高的血清尿酸水平相关的病症的药物组合物，方法和试剂盒，其包括施用包含第一次尿酸盐降低剂和第二次降低尿酸的组合物 代理商 在一些方面，第一种降低尿酸的药剂是（ - ） - 氟酸盐，（ - ） - 卤味酸或其药学上可接受的盐。 在一些方面，第二种尿酸降低剂是尿酸生产的抑制剂，尿酸排泄剂，尿酸酶或其药学上可接受的盐。